Skip to main content
Kevin Kalinsky, MD, Oncology, Atlanta, GA

Kevin M Kalinsky MD MS

Oncology•Atlanta, GA

Hematologic Oncology

Associate Professor of Medicine, Winship Cancer Institute at Emory University

Join to view full profile

  • 1365 Clifton Rd NEAtlanta, GA 30322

  • Phone+1 404-778-1900

  • Fax+1 212-305-0178

Dr. Kalinsky is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.
See Dr. Kalinsky's full profileAlready have an account?

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2008 - 2009
  • Tufts Medical Center
    Tufts Medical CenterFellowship, Hematology and Medical Oncology, 2005 - 2008
  • Tufts Medical Center
    Tufts Medical CenterResidency, Internal Medicine, 2002 - 2005
  • Medical University of South Carolina
    Medical University of South CarolinaClass of 2002

Certifications & Licensure

  • GA State Medical License
    GA State Medical License 2020 - 2027
  • NY State Medical License
    NY State Medical License 2008 - 2027
  • MA State Medical License
    MA State Medical License 2006 - 2008
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification Allscripts TouchWorks EHR, Allscripts, 2013, 2015-2017
  • CMS Meaningful Use Stage 2 Certification Allscripts TouchWorks EHR (Complete), Allscripts, 2013, 2015-2017
  • CMS Meaningful Use Stage 2 Certification Allscripts TouchWorks EHR, Allscripts, 2013, 2015-2017

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Effect of Capivasertib in Patients with an AKT1 E17K-Mutated Tumor  
    Kevin Kalinsky, Barbara A Conley, Lyndsay N Harris, Carlos L Arteaga, Alice P Chen, Keith T Flaherty, JAMA Oncology

Lectures

  • Enhancing Checkpoint Inhibitors in Triple-Negative Breast Cancer. Breast Cancer Immunotherapy: Can We Crack the Code? 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
  • Phase IB trial of ACY-1215 (Ricolinostat) combined with nab-paclitaxel in metastatic breast cancer. 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

  • ASCENT-04 Exploratory Analysis: Sacituzumab Govitecan Plus Pembrolizumab Improves PFS2, Delays Next Treatment
    ASCENT-04 Exploratory Analysis: Sacituzumab Govitecan Plus Pembrolizumab Improves PFS2, Delays Next TreatmentSeptember 2nd, 2026
  • New Frontline Standard or Not? Triple-Negative Breast Cancer Data Spark Debate
    New Frontline Standard or Not? Triple-Negative Breast Cancer Data Spark DebateJune 8th, 2026
  • Sacituzumab Govitecan with Pembrolizumab Extends PFS2 in PD–L1–Positive Metastatic Triple-Negative Breast Cancer
    Sacituzumab Govitecan with Pembrolizumab Extends PFS2 in PD–L1–Positive Metastatic Triple-Negative Breast CancerJune 2nd, 2026

Grant Support

  • Breast Cancer Brain Metastasis Therapy by Focused Ultrasound-Guided Control of HER2 CAR T cellsGEORGIA INSTITUTE OF TECHNOLOGY2023–2028

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence:

Dr. Kevin Kalinsky, Dr. Kevin Kalinsky, MD, Dr. K Kalinsky, Dr. Kevin M Kalinsky